Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Alkermes Plc (ALKS)  
$27.25 0.47 (1.76%) as of 4:30 Wed 3/27


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 183,678,000
Market Cap: 5.01(B)
Last Volume: 775,760 Avg Vol: 773,548
52 Week Range: $23.37 - $33.63
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Delivery

Member Indexes:

    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  581
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Alkermes is a biopharmaceutical company. Co. has a portfolio of marketed products focused on central nervous system disorders such as addiction and schizophrenia and a pipeline of product candidates in the fields of neuroscience and oncology. Co.'s proprietary products include: ARISTADA, which is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia; ARISTADA INITIO, which is indicated for the initiation of ARISTADA when used for the treatment of schizophrenia in adults; and VIVITROL, which is for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 35,000
Total Buy Value $0 $0 $0 $815,735
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 15,666 15,666 89,488 296,961
Total Sell Value $454,291 $454,291 $2,700,159 $8,679,342
Total People Sold 3 3 4 7
Total Sell Transactions 3 3 7 17
End Date 2023-12-28 2023-09-26 2023-03-28 2022-03-28

   
Records found: 1496
  Page 1 of 60  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Nichols Christian Todd SVP, Chief Commercial Officer   •       •      –    2024-03-18 4 AS $28.10 $292,740 D/D (10,417) 65,911 -1%     
   Parisi Samuel Joseph VP, Finance (Interim PAO)   •       •      –    2024-02-27 4 S $29.65 $75,874 D/D (2,559) 7,717 10%     
   Nichols Christian Todd SVP, Chief Commercial Officer   •       •      –    2024-02-23 4 D $29.57 $84,127 D/D (2,845) 76,328     -
   Nichols Christian Todd SVP, Chief Commercial Officer   •       •      –    2024-02-23 4 OE $0.00 $0 D/D 6,407 79,173     -
   Parisi Samuel Joseph VP, Finance (Interim PAO)   •       •      –    2024-02-23 4 D $29.57 $19,871 D/D (672) 10,276     -
   Parisi Samuel Joseph VP, Finance (Interim PAO)   •       •      –    2024-02-23 4 OE $0.00 $0 D/D 2,283 10,948     -
   Jackson Blair Curtis EVP, Chief Operating Officer   •       •      –    2024-02-23 4 D $29.57 $114,732 D/D (3,880) 157,802     -
   Jackson Blair Curtis EVP, Chief Operating Officer   •       •      –    2024-02-23 4 OE $0.00 $0 D/D 8,737 161,682     -
   Gaffin David Joseph EVP, CLO, Alkermes, Inc.   •       •      –    2024-02-23 4 D $29.57 $100,952 D/D (3,414) 164,782     -
   Gaffin David Joseph EVP, CLO, Alkermes, Inc.   •       •      –    2024-02-23 4 OE $0.00 $0 D/D 7,689 168,196     -
   Landine Michael J SVP, Corp Dev., Alkermes, Inc.   •       •      –    2024-02-23 4 D $29.57 $53,551 D/D (1,811) 281,730     -
   Landine Michael J SVP, Corp Dev., Alkermes, Inc.   •       •      –    2024-02-23 4 OE $0.00 $0 D/D 4,077 283,541     -
   Brown Iain Michael SVP, Chief Financial Officer   •       •      –    2024-02-23 4 D $29.57 $76,498 D/D (2,587) 116,344     -
   Brown Iain Michael SVP, Chief Financial Officer   •       •      –    2024-02-23 4 OE $0.00 $0 D/D 5,825 118,931     -
   Hopkinson Craig C. EVP R&D, Chief Medical Officer   •       •      –    2024-02-23 4 D $29.57 $100,952 D/D (3,414) 109,709     -
   Hopkinson Craig C. EVP R&D, Chief Medical Officer   •       •      –    2024-02-23 4 OE $0.00 $0 D/D 7,689 113,123     -
   Hopkinson Craig C. EVP R&D, Chief Medical Officer   •       •      –    2024-02-22 4 D $28.91 $157,617 D/D (5,452) 105,434     -
   Hopkinson Craig C. EVP R&D, Chief Medical Officer   •       •      –    2024-02-22 4 OE $0.00 $0 D/D 12,278 110,886     -
   Gaffin David Joseph EVP, CLO, Alkermes, Inc.   •       •      –    2024-02-22 4 D $28.91 $95,403 D/D (3,300) 160,507     -
   Gaffin David Joseph EVP, CLO, Alkermes, Inc.   •       •      –    2024-02-22 4 OE $0.00 $0 D/D 7,431 163,807     -
   Brown Iain Michael SVP, Chief Financial Officer   •       •      –    2024-02-22 4 D $28.91 $91,240 D/D (3,156) 113,106     -
   Brown Iain Michael SVP, Chief Financial Officer   •       •      –    2024-02-22 4 OE $0.00 $0 D/D 7,108 116,262     -
   Landine Michael J SVP, Corp Dev., Alkermes, Inc.   •       •      –    2024-02-22 4 D $28.91 $55,767 D/D (1,929) 279,464     -
   Landine Michael J SVP, Corp Dev., Alkermes, Inc.   •       •      –    2024-02-22 4 OE $0.00 $0 D/D 5,654 281,393     -
   Jackson Blair Curtis EVP, Chief Operating Officer   •       •      –    2024-02-22 4 D $28.91 $124,429 D/D (4,304) 152,945     -

  1496 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 60
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed